StockNews.AI
CRNX
StockNews.AI
130 days

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

1. Crinetics to report Q1 2025 financial results on May 8. 2. Management will hold a conference call at 4:30 p.m. ET. 3. Lead candidate paltusotine targets acromegaly and carcinoid syndrome. 4. Company focuses on therapeutics for endocrine diseases. 5. Conference call will be available via webcast.

Earnings
+8.42%Current Return
VS
+1.78%S&P 500
$26.8504/11 08:05 AM EDTEvent Start
$29.1104/14 08:24 AM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

Upcoming financial results can influence stock price based on performance. Past earnings announcements caused variable market reactions based on reported progress in clinical trials.

How important is it?

Earnings reports significantly influence investor confidence and stock price. The introduction of potential new therapies can create speculative interest but results could vary.

Why Short Term?

Immediate impact expected from May 8 results, influencing investor sentiment. Historical earnings often cause short-term volatility in biotech stocks like CRNX.

Related Companies

April 11, 2025 08:00 ET  | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 8 @ 4:30 p.m. ET Domestic:1-833-470-1428International:1-404-975-4839Conference ID:CRNXQ1 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call. The webcast will be archived on the Investor Relations section of www.crinetics.com. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Investors:Gayathri DiwakarHead of Investor Relationsgdiwakar@crinetics.com (858) 345-6340 Media: Natalie BadilloHead of Corporate Communications nbadillo@crinetics.com (858) 345-6075

Related News